Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein.
Torres N, Regge MV, Secchiari F, Friedrich AD, Spallanzani RG, Raffo Iraolagoitia XL, Núñez SY, Sierra JM, Ziblat A, Santilli MC, Gilio N, Almada E, Lauche C, Pardo R, Domaica CI, Fuertes MB, Madauss KP, Hance KW, Gloger IS, Zylberman V, Goldbaum FA, Zwirner NW. Torres N, et al. Among authors: gloger is. J Immunother Cancer. 2020 Jun;8(1):e000233. doi: 10.1136/jitc-2019-000233. Epub 2020 Jun 8. J Immunother Cancer. 2020. PMID: 32518090 Free PMC article.
AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress.
Villafañez F, García IA, Carbajosa S, Pansa MF, Mansilla S, Llorens MC, Angiolini V, Guantay L, Jacobs H, Madauss KP, Gloger I, Gottifredi V, Bocco JL, Soria G. Villafañez F, et al. Oncogene. 2019 May;38(22):4310-4324. doi: 10.1038/s41388-019-0724-7. Epub 2019 Jan 31. Oncogene. 2019. PMID: 30705406 Free PMC article.
Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Carbajosa S, Pansa MF, Paviolo NS, Castellaro AM, Andino DL, Nigra AD, García IA, Racca AC, Rodriguez-Berdini L, Angiolini V, Guantay L, Villafañez F, Federico MB, Rodríguez-Baili MC, Caputto BL, Drewes G, Madauss KP, Gloger I, Fernandez E, Gil GA, Bocco JL, Gottifredi V, Soria G. Carbajosa S, et al. Clin Cancer Res. 2019 Jul 1;25(13):4049-4062. doi: 10.1158/1078-0432.CCR-18-3516. Epub 2019 Mar 19. Clin Cancer Res. 2019. PMID: 30890549
ADAMTSL3 as a candidate gene for schizophrenia: gene sequencing and ultra-high density association analysis by imputation.
Dow DJ, Huxley-Jones J, Hall JM, Francks C, Maycox PR, Kew JN, Gloger IS, Mehta NA, Kelly FM, Muglia P, Breen G, Jugurnauth S, Pederoso I, St Clair D, Rujescu D, Barnes MR. Dow DJ, et al. Among authors: gloger is. Schizophr Res. 2011 Apr;127(1-3):28-34. doi: 10.1016/j.schres.2010.12.009. Epub 2011 Jan 15. Schizophr Res. 2011. PMID: 21239144
Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma.
Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, Fox SM, Gibson RA, Gormley DA, Holbrook JD, Hunter AJ, Kinsey EE, Prinjha R, Richardson JC, Roses AD, Smith MA, Tsokanas N, Willé DR, Wu W, Yates JW, Gloger IS. Cutler P, et al. Among authors: gloger is. Proteomics Clin Appl. 2008 Apr;2(4):467-77. doi: 10.1002/prca.200780101. Epub 2008 Mar 7. Proteomics Clin Appl. 2008. PMID: 21136851
24 results